Migoprotafib (GDC-1971) is a potent and highly selective SHP2 (Src Homology-2 Domain-Containing Phosphatase 2) inhibitor for the study of advanced solid tumours.

Migoprotafib is a selective SHP2 inhibitor that demonstrates potent antiproliferative activity in various tumor cell lines (e.g., NCI-H358, KYSE520, and LoVo). In vitro, Migoprotafib (0.001–10 μM, 2–6 days) alone or in combination with KRAS G12C inhibitors (e.g., GDC-6036) significantly suppressed pERK levels and induced cell cycle arrest, indicating effective MAPK pathway inhibition[1].

In mouse xenograft models, Migoprotafib (30–60 mg/kg, oral gavage, once daily) showed strong antitumor efficacy, particularly in combination with KRAS G12C inhibitors (e.g., GDC-6036), resulting in complete or substantial tumor regression (treatment up to 21 days)[1].